Shuming Liu

Research

Research/Expertise: Inhibitors of DNA repair enzyme RAD54 for development of novel and efficient cancer therapies.

Publications

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2015. doi: 10.1038.

Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK. Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget. 2015 Aug 28;6(25):20885-901.

Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018. pii: jem.20171046. doi: 10.1084/jem.20171046.

Revach, O. Y., Liu, S., Jenkins, R. W. Targeting TANK-binding kinase 1 (TBK1) in cancer. Expert Opin Ther Targets, 2020 doi:10.1080/14728222.2020.1826929.

Sun, Y., Revach, Oy., Anderson, S., Liu, S., Jenkins, R.W. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature 2023. https://doi.org/10.1038/s41586-023-05704-6